Filing Flows › Travere Therapeutics (TVTX) › Q2 2026
Travere Therapeutics (TVTX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 4, 2026
Travere Therapeutics (TVTX) reported revenue of $170M for the second quarter 2026 (Q2 2026), +48% from a year earlier and +33% from the quarter before. Operating margin was 2.3%, net loss $34.8M (20.5% of revenue).
Travere Therapeutics, Q2 2026: revenue $170M (+48% year over year), operating margin 2.3%, net loss $34.8M, operating cash flow $58.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $170M | +33% | +48% |
| Operating profit | $4.0M | — | — |
| Net earnings | −$34.8M | — | — |
| Operating cash flow | $58.1M | — | 12× |
What changed
Revenue was $169.6M in Q2 2026, up 48% year over year and up 33% from the previous quarter. FILSPARI was the largest line at 83% of revenue. FILSPARI added $69.2M year over year (up 96%), 125% of the total change. License and collaboration revenue declined 58%.
Operating profit was $4.0M, a 2.3% margin (up 13.4 points year over year). Total costs grew 30% against revenue growth of 48%. The fastest-growing cost line was SG&A (+54%). The quarter ended with a net loss of $34.8M, narrower than the previous quarter's $37.1M loss. Net interest and other expense of $39.0M was the main reason.
Operating cash flow was $58.1M (up 1065% year over year). Non-cash charges added back $4.2M of depreciation and amortization and $21.8M of share-based compensation. Working capital and other items added $66.8M.
Questions
What was Travere Therapeutics' revenue in the second quarter 2026?
Travere Therapeutics (TVTX) reported revenue of $170M for the second quarter 2026 (Q2 2026), +48% from a year earlier and +33% from the quarter before.
Was Travere Therapeutics profitable in the second quarter 2026?
Operating profit was $4.0M (2.3% of revenue) and net loss $34.8M.